Related Experiment Video

Updated: Jul 5, 2025

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture
10:38

Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture

Published on: November 22, 2019

9.0K

ID2 Promotes Lineage Transition of Prostate Cancer through FGFR and JAK-STAT Signaling

Jinxiong Zhang1, Zhihao Chen1, Yongxin Mao1

  • 1Department of Urology, Huadong Hospital Affiliated to Fudan University, Shanghai 200040, China.

Cancers
|January 23, 2024
PubMed

Insights

Increased ID2 expression drives aggressive AR-null prostate cancer (PCa) and resistance to enzalutamide. This study identifies ID2 as a key factor in PCa progression and a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Androgen receptor pathway inhibitors (ARPIs) increase AR-null prostate cancer (PCa), including neuroendocrine PCa (NEPC) and double-negative PCa (DNPC).
  • The mechanism driving this lineage transition remains unclear.

Purpose of the Study:

  • To investigate the role of ID2 in AR-null PCa development and enzalutamide resistance.
  • To identify biomarkers for predicting treatment response and patient prognosis.

Main Methods:

  • In vitro and in vivo studies to assess ID2 function in PCa cells.
  • Generation of an ID2 UP50 signature for resistance prediction.
  • Analysis of signaling pathways (JAK/STAT, FGFR, AR) affected by ID2.

Main Results:

  • ID2 expression is elevated in AR-null PCa.
  • ID2 promotes PCa malignancy and confers resistance to enzalutamide.
  • The ID2 UP50 signature predicts enzalutamide resistance and patient prognosis.
  • ID2 activates stemness pathways (JAK/STAT, FGFR) and inhibits AR signaling.

Conclusions:

  • ID2 is strongly associated with the acquisition of a stem-like phenotype in PCa cells.
  • ID2 contributes to resistance against androgen deprivation therapy (ADT) and next-generation ARPIs.
  • ID2 represents a potential therapeutic target for overcoming treatment resistance in advanced PCa.
Keywords:
FGFR signalingID2ID2 UP50 signaturelineage transitionprostate cancer

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.2K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.4K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.1K